[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Merck & Company (MRK)

Merck & Company (MRK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 375,503,616
  • Shares Outstanding, K 2,467,172
  • Annual Sales, $ 65,011 M
  • Annual Income, $ 18,254 M
  • EBIT $ 6,984 M
  • EBITDA $ 12,822 M
  • 60-Month Beta 0.19
  • Price/Sales 5.13
  • Price/Cash Flow 11.83
  • Price/Book 7.95

Options Overview Details

View History
  • Implied Volatility 30.48% (-4.22%)
  • Historical Volatility 39.38%
  • IV Percentile 61%
  • IV Rank 64.08%
  • IV High 35.42% on 04/27/26
  • IV Low 21.66% on 12/08/25
  • Expected Move (DTE 1) 2.33 (1.54%)
  • Put/Call Vol Ratio 0.46
  • Today's Volume 50,716
  • Volume Avg (30-Day) 31,129
  • Put/Call OI Ratio 0.77
  • Today's Open Interest 547,201
  • Open Int (30-Day) 454,262
  • Expected Range 148.83 to 153.49

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 28 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $2.27
  • Number of Estimates 5
  • High Estimate $2.41
  • Low Estimate $2.20
  • Prior Year $2.58
  • Growth Rate Est. (year over year) -12.02%

Price Performance

See More
Period Period Low Period High Performance
1-Month
124.10 +21.89%
on 07/21/26
153.50 -1.46%
on 08/19/26
+26.86 (+21.59%)
since 07/20/26
3-Month
111.57 +35.57%
on 06/18/26
153.50 -1.46%
on 08/19/26
+38.26 (+33.86%)
since 05/20/26
52-Week
77.58 +94.97%
on 09/25/25
153.50 -1.46%
on 08/19/26
+66.60 (+78.67%)
since 08/20/25

Most Recent Stories

More News
Stocks Finish Mixed as Bond Yields Fall and Chipmakers Slide

The S&P 500 Index ($SPX ) (SPY ) closed up by +0.21% on Wednesday, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up by +0.22%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down by -0.22%....

MSTR : 111.21 (+6.68%)
HL : 20.78 (+1.17%)
SNDK : 1,581.36 (+0.80%)
CDE : 21.00 (+0.33%)
GLXY : 22.83 (+4.25%)
TRI : 106.25 (+1.24%)
COIN : 171.48 (+7.04%)
STX : 849.24 (+2.00%)
WDC : 465.68 (+0.78%)
AMD : 461.81 (-0.99%)
CMC : 65.44 (-3.99%)
SCCO : 197.82 (+1.61%)
Huge Unusual Put Options Volume in Merck - Is MRK Stock Overvalued?

A Barchart report shows that despite recent strong Q2 results and a 10% spike in Merck stock today, an unusually large volume of put options has traded at a much lower strike price. Is MRK stock overvalued?...

MRK : 150.60 (-1.05%)
Merck (MRK) Stock Trades Up, Here Is Why

Merck (MRK) Stock Trades Up, Here Is Why

MRK : 150.60 (-1.05%)
This Analyst Just Upgraded Moderna as MRNA Stock Skyrockets on Cancer Vaccine Results

Moderna stock rips higher on a major cancer breakthrough. The announcement led William Blair to upgrade MRNA shares to "Outperform."

MRK : 150.60 (-1.05%)
MRNA : 133.85 (-23.24%)
Stocks Supported by Lower Bond Yields

The S&P 500 Index ($SPX ) (SPY ) is up by +0.58% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up by +0.55%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up by +0.07%. E-mini S&P futures (ESU26...

MSTR : 111.21 (+6.68%)
HL : 20.78 (+1.17%)
CDE : 21.00 (+0.33%)
GLXY : 22.83 (+4.25%)
TRI : 106.25 (+1.24%)
COIN : 171.48 (+7.04%)
STX : 849.24 (+2.00%)
WDC : 465.68 (+0.78%)
AMD : 461.81 (-0.99%)
SCCO : 197.82 (+1.61%)
^BTCUSD : 72,512.76 (+5.07%)
SPY : 763.78 (-0.69%)
Stocks Mixed on Lower Bond Yields and Chip Stock Weakness

The S&P 500 Index ($SPX ) (SPY ) is up by +0.33% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up by +0.47%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -0.33%. E-mini S&P futures...

AMAT : 489.10 (-1.32%)
B : 46.28 (+2.55%)
AVGO : 364.00 (+0.42%)
HL : 20.78 (+1.17%)
INTU : 364.08 (+0.44%)
SNDK : 1,581.36 (+0.80%)
CDE : 21.00 (+0.33%)
MRK : 150.60 (-1.05%)
TRI : 106.25 (+1.24%)
$IUXX : 29,130.99 (-1.00%)
ZNU26 : 108-160 (-0.26%)
ESU26 : 7,673.25 (-0.72%)
Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma

First and only combination regimen to demonstrate statistically significant and clinically meaningful improvements in RFS and DMFS compared to KEYTRUDA alone for these patients in the adjuvant melanoma...

MRK : 150.60 (-1.05%)
MRNA : 133.85 (-23.24%)
5 Insightful Analyst Questions From Merck’s Q2 Earnings Call

5 Insightful Analyst Questions From Merck’s Q2 Earnings Call

MRK : 150.60 (-1.05%)
Merck & Co’s Stock: Analyst Estimates & Ratings

Merck has outperformed the broader market over the past year, and analysts remain optimistic about the stock.

XLV : 173.45 (-1.27%)
$SPX : 7,651.60 (-0.73%)
MRK : 150.60 (-1.05%)
U.S. FDA Accepts sBLA for ENFLONSIA™ (clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Risk for Severe RSV for Their Second Season

EMA also accepts application for the same population for ENFLONSIA based on results from the Phase 3 SMART trial If approved, children under two years of age at increased...

MRK : 150.60 (-1.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 80%. The market is in extreme overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda,...

See More

Key Turning Points

3rd Resistance Point 164.10
2nd Resistance Point 158.80
1st Resistance Point 155.50
Last Price 150.60
1st Support Level 146.90
2nd Support Level 141.60
3rd Support Level 138.30

See More

52-Week High 153.50
Last Price 150.60
Fibonacci 61.8% 124.50
Fibonacci 50% 115.54
Fibonacci 38.2% 106.58
52-Week Low 77.58

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.